Vector Building Products ("Vector") is excited to announce its launch as a premier specialty building products distribution platform with its initial partnership with Spectrum Resource, a leading ...
Results demonstrate a significant survival benefit in the cTMB-H / HRP subset: median OS of almost 6 years (68 months) with Vigil vs. less than 2 ...
Findings from a phase I trial (NCT04183166) evaluating TG4050, a neoantigen therapeutic vaccine, in patients with operable, ...
AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, recently announced that the United States Food and Drug Administration (FDA) has ...
TG4050 elicits strong polyepitopic, polyclonal, durable cytotoxic and effector neoantigen-specific CD8 T cell responses Results reinforce TG4050 ...
Ocugen has announced the publication of positive results from its phase 1 GARDian1 trial of OCU410ST, a gene therapy for ...
Organisations need to rethink speed, automation and identity risk as artificial intelligence (AI) continues to amplify ...
Compute remains essential, but the ability to translate that compute into reliable, repeatable outcomes is where competitive ...
It was the priciest biotech startup sale in North Carolina history. Now five years under Bayer, AskBio advances more AAV gene ...
Microsoft’s investigation into RedVDS services and infrastructure uncovered a global network of disparate cybercriminals ...
MedPage Today on MSN
Autoimmune Anemia Is the Latest Condition Found Responsive to CAR-T Therapy
Eleven patients with refractory autoimmune hemolytic anemia (AIHA) were all brought into drug-free remission with CAR T-cell ...
First dose-expansion patient successfully received SB-007 SB-007 addresses the root cause of Stargardt disease with the potential to treat patients across all ABCA4 mutations SB-007 granted FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback